EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 30 / Numéro 1 (Janvier 2014) Med Sci (Paris), 30 1 (2014) 69-75 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 1, Janvier 2014
Page(s) 69 - 75
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143001016
Publié en ligne 24 janvier 2014
  1. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012 ; 366 : 1275–1286. [CrossRef] [PubMed] [Google Scholar]
  2. Tomaras GD, Ferrari G, Shen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA 2013 ; 110 : 9019–9024. [CrossRef] [Google Scholar]
  3. McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 2012 ; 13 : 423–427. [CrossRef] [PubMed] [Google Scholar]
  4. Montefiori DC, Karnasuta C, Huang Y, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012 ; 206 : 431–441. [CrossRef] [PubMed] [Google Scholar]
  5. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010 ; 28 : 413–444. [CrossRef] [PubMed] [Google Scholar]
  6. Moog C, Fleury HJ, Pellegrin I, et al. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997 ; 71 : 3734–3741. [PubMed] [Google Scholar]
  7. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011 ; 477 : 466–470. [CrossRef] [PubMed] [Google Scholar]
  8. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009 ; 458 : 636–640. [CrossRef] [PubMed] [Google Scholar]
  9. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012 ; 37 : 412–425. [CrossRef] [PubMed] [Google Scholar]
  10. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000 ; 6 : 207–210. [CrossRef] [PubMed] [Google Scholar]
  11. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009 ; 15 : 951–954. [CrossRef] [PubMed] [Google Scholar]
  12. Holl V, Peressin M, Decoville T, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006 ; 80 : 6177–6181. [CrossRef] [PubMed] [Google Scholar]
  13. Holl V, Peressin M, Schmidt S, et al. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 2006 ; 107 : 4466–4474. [CrossRef] [PubMed] [Google Scholar]
  14. Peressin M, Holl V, Schmidt S, et al. HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies. J Virol 2011 ; 85 : 1077–1085. [CrossRef] [PubMed] [Google Scholar]
  15. Moody MA, Liao HX, Alam SM, et al. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med 2010 ; 207 : 763–776. [CrossRef] [PubMed] [Google Scholar]
  16. Su B, Xu K, Lederle A, et al. Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T-lymphocytes. Blood 2012 ; 120 : 3708–3717. [CrossRef] [PubMed] [Google Scholar]
  17. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007 ; 262 : 5–25. [CrossRef] [PubMed] [Google Scholar]
  18. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007 ; 449 : 101–104. [CrossRef] [PubMed] [Google Scholar]
  19. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011 ; 108 : 11181–11186. [CrossRef] [Google Scholar]
  20. Moog C, Dereuddre-Bosquet N, Teillaud JL, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 2013 ; doi : 10.1038/mi.2013.23. [Google Scholar]
  21. Connick E, Marr DG, Zhang XQ, et al. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retrovir 1996 ; 12 : 1129–1140. [CrossRef] [Google Scholar]
  22. Holl V, Hemmerter S, Burrer R, et al. Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J Immunol 2004 ; 173 : 6274–6283. [PubMed] [Google Scholar]
  23. Lambotte O. Les patients HIV controllers. Med Sci (Paris) 2012 ; 28 : 172–178. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Mestecky J, Jackson S, Moldoveanu Z, et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retrovir 2004 ; 20 : 972–988. [CrossRef] [Google Scholar]
  25. Broliden K, Hinkula J, Devito C, et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001 ; 79 : 29–36. [CrossRef] [PubMed] [Google Scholar]
  26. Mantis NJ, Palaia J, Hessell AJ, et al. Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol 2007 ; 179 : 3144–3152. [PubMed] [Google Scholar]
  27. Stieh G, McRaven M, Cianci G, et al. Development of an imaging based virus aggregation assay for vaccine development. Retrovirology 2012 ; 9 : 319. [CrossRef] [Google Scholar]
  28. Watkins JD, Sholukh AM, Mukhtar MM, et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 2013 ; 27 : F13–F20. [CrossRef] [PubMed] [Google Scholar]
  29. Laurence J, Saunders A, Early E, Salmon JE. Human immunodeficiency virus infection of monocytes: relationship to Fc-gamma receptors and antibody-dependent viral enhancement. Immunology 1990 ; 70 : 338–343. [PubMed] [Google Scholar]
  30. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003 ; 13 : 387–398. [CrossRef] [PubMed] [Google Scholar]
  31. Forthal DN, Gabriel EE, Wang A, et al. Association of Fcgamma receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 2012 ; 120 : 2836–2842. [CrossRef] [PubMed] [Google Scholar]
  32. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012 ; 30 : 423–433. [CrossRef] [PubMed] [Google Scholar]
  33. Moldt B, Schultz N, Dunlop DC, et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcgamma receptors to define the role of effector functions in protection against HIV. J Virol 2011 ; 85 : 10572–10581. [CrossRef] [PubMed] [Google Scholar]
  34. Moldt B, Shibata-Koyama M, Rakasz EG, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012 ; 86 : 6189–6196. [CrossRef] [PubMed] [Google Scholar]
  35. Ruffin N, Borggren M, Euler Z, et al. Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011. J Transl Med 2012 ; 10 : 144. [CrossRef] [PubMed] [Google Scholar]
  36. PX’Therapeutics. PX’Therapeutics annonce l’essai clinique EuroNeut-41 portant sur un vaccin prophylactique contre le VIH. Business Wire 2012 ; 12 mars. [Google Scholar]
  37. Ng CT, Jaworski JP, Jayaraman P, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 2010 ; 16 : 1117–1119. [CrossRef] [PubMed] [Google Scholar]
  38. Michaud HA, Gomard T, Gros L, et al. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog 2010 ; 6 : e1000948. [CrossRef] [PubMed] [Google Scholar]
  39. Abes R, Gelize E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010 ; 116 : 926–934. [CrossRef] [PubMed] [Google Scholar]
  40. Schwartz C, Le Douce V, Cherrier T, et al. Un virus tapi dans l’ombre : les bases moléculaires de la latence du VIH-1. Med Sci (Paris) 2010 ; 26 : 159–164. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  41. Le Tortorec A, Dejucq-Rainsford N. Le tractus génital masculin. Med Sci (Paris) 2010 ; 26 : 861–868. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  42. Abès R, Dutertre CA, Teillaud JL. Les anticorps : mieux les connaître pour mieux s’en servir. Med Sci (Paris) 2009 ; 25 : 1011–1019. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  43. Deligne C, Teillaud JL. Le double visage des anticorps monoclonaux en oncologie. Med Sci (Paris) 2013 ; 29 : 57–63. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.